Want to see JP:206A full AI Analyst Report?
PRISM BioLab Co. LTD (206A) AI Stock Analysis
Top Page
PRISM BioLab Co. LTD
(TSE/TYO:206A)
The score is held down primarily by persistent large losses and worsening/volatile cash burn, which elevates execution and funding risk. Technicals reinforce the caution, with the stock below major moving averages and weak momentum indicators. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
PRISM BioLab Co. LTD (206A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.88B
- Dividend Yield
- ―
- Average Volume (3M)
- 89.57K
- Price to Earnings (P/E)
- -5.6
- Beta (1Y)
- 0.98
- Revenue Growth
- 84.23%
- EPS Growth
- 33.14%
- Country
- Japan
- Employees
- 35
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
PRISM BioLab Co. LTD Business Overview & Revenue Model
Company Description
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-he...
How the Company Makes Money
PRISM BioLab primarily makes money through partnering and licensing its drug discovery programs and related intellectual property to larger pharmaceutical or biotechnology companies. Revenue typically comes from (1) upfront payments received when a c...
PRISM BioLab Co. LTD Financial Statement Overview
Summary
Despite sharp recent revenue growth and a debt-free balance sheet, the company remains deeply unprofitable (negative EBIT and net income) with heavily negative margins. Cash flow is a major weakness: operating cash flow is meaningfully negative and free cash flow is negative in most years with an accelerating burn in the latest year, increasing funding risk.
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 677.33M | 305.62M | 112.93M | 554.40M |
| Gross Profit | 269.76M | 160.54M | 80.31M | 535.14M |
| EBITDA | -831.28M | -1.05B | -488.13M | 67.89M |
| Net Income | -833.70M | -1.05B | -526.91M | 72.96M |
Balance Sheet | ||||
| Total Assets | 3.09B | 4.53B | 1.21B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 4.39B | 1.13B | 1.69B |
| Total Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 376.86M | 1.03B | 63.41M | 65.23M |
| Stockholders Equity | 2.71B | 3.50B | 1.15B | 1.67B |
Cash Flow | ||||
| Free Cash Flow | -1.53B | -61.55M | -548.40M | 97.25M |
| Operating Cash Flow | -1.47B | 150.14M | -513.81M | 102.96M |
| Investing Cash Flow | -69.01M | -244.19M | -40.38M | -7.87M |
| Financing Cash Flow | 33.59M | 3.37B | 0 | 110.87M |
PRISM BioLab Co. LTD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Negative. The current price of 132.00 is below the 20-day moving average (MA) of 137.45, below the 50-day MA of 156.42, and below the 200-day MA of 167.64, indicating a bearish trend. The MACD of -6.84 indicates Negative momentum. The RSI at 35.36 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:206A.
PRISM BioLab Co. LTD Peers Comparison
Overall Rating
JP:488045Neutral- JP:206A43Neutral
JP:497842Neutral
JP:777442Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4880 | 45Neutral | JPY 5.68B | 57.55 | ― | 1.75% | -9.94% | ― |
| JP:206A | 43Neutral | JPY 4.89B | -5.57 | ― | ― | 84.23% | 33.14% |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:206A | PRISM BioLab Co. LTD | 132.00 | -5.00 | -3.65% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4880 | CellSource Co., Ltd. | 286.00 | -225.00 | -44.03% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
PRISM BioLab Co. LTD Corporate Events
PRISM BioLab’s Revenue Rises but Losses Deepen and Equity Shrinks
PRISM BioLab reported non-consolidated revenue of ¥369 million for the nine months to June 30, 2026, up 19.4% year on year, but continued to post operating and net losses, with net income at a loss of ¥845 million and basic earnings per sha...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026